E-resources
Peer reviewed
Open access
-
Sun, Shan-Liang; Wu, Jia-Zhen; Wang, Jing-Jing; Zhou, Hai; Zhang, Chen-Qian; Tong, Zhen-Jiang; Wang, Yi-Bo; Sha, Jiu-Kai; Wang, Qing-Xin; Liu, Jia-Chuan; Zheng, Xin-Rui; Li, Qing-Qing; Zhang, Meng-Yuan; Yang, Jin; Wei, Tian-Hua; Wang, Zi-Xuan; Yu, Yan-Cheng; Ding, Ning; Leng, Xue-Jiao; Xue, Xin; Li, He-Min; Dai, Wei-Chen; Yin, Xiao-Ying; Yang, Ye; Duan, Jin-Ao; Li, Nian-Guang; Shi, Zhi-Hao
Biomedicine & pharmacotherapy, 12/2023, Volume: 169Journal Article
The therapeutic benefits of available FLT3 inhibitors for AML are limited by drug resistance, which is related to mutations, as well toxicity caused by off-target effects. In this study, we introduce a new small molecule FLT3 inhibitor called danatinib, which was designed to overcome the limitations of currently approved agents. Danatinib demonstrated greater potency and selectivity, resulting in cytotoxic activity specific to FLT3-ITD and/or FLT3-TKD mutated models. It also showed a superior kinome inhibition profile compared to several currently approved FLT3 inhibitors. In diverse FLT3-TKD models, danatinib exhibited substantially improved activity at clinically relevant doses, outperforming approved FLT3 inhibitors. In vivo safety evaluations performed on the granulopoiesis of transgenic myeloperoxidase (MPO) zebrafish and mice models proved danatinib to have an acceptable safety profile. Danatinib holds promise as a new and improved FLT3 inhibitor for the treatment of AML, offering long-lasting remissions and improved overall survival rates. Display omitted •Danatinib displayed increased potency and selectivity.•Danatinib showed a superior kinome inhibition profile.•Danatinib significantly enhanced activity at clinically relevant doses.•Danatinib had an acceptable safety profile.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.